Lilly adds to immune drug pipeline with $2.9B Merida buyout
The big drugmaker’s latest company acquisition this year is centered around a technology designed to degrade proteins that malfunction in autoimmune disorders.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.